Tumor Aneuploidy Score As A Predictor Of Immunotherapy Response
SUMMARY
Tumor aneuploidy scoring delivers improved immunotherapy response prediction, enhancing personalized cancer treatment by providing prognostic insights beyond existing biomarkers like tumor mutational burden.
The Unmet Need: Reliable biomarkers to predict immunotherapy efficacy for patients with low tumor mutational burden
- Current immunotherapy biomarkers, including PD-L1 expression and tumor mutational burden (TMB),inadequately predict patient response, especially in individuals with low TMB tumors where outcome variability limits treatment optimization. This gap impedes the effective personalization of immunotherapy and radiotherapy combinations, contributing to suboptimal clinical outcomes in non-small cell lung cancer and other malignancies
- Advances in genomic profiling and precision oncology underscore a growing emphasis on integrating multi-parametric biomarkers to refine therapeutic decision-making, creating a critical opportunity to leverage tumor aneuploidy scores as complementary prognostic indicators.
The Proposed Solution: Predicting immunotherapy response and survival through tumor aneuploidy scoring across multiple cancer types
- The faculty inventor developed a tumor aneuploidy score derived from genomic analyses as an independent prognostic biomarker, particularly for patients with low TMB, to forecast survival following immune checkpoint blockade (ICB) therapies; this scoring enhances stratification beyond current markers and informs combined treatment strategies such as concurrent radiotherapy. Validated through extensive clinical trial data and published in leading journals, the method differentiates prognostic outcomes with higher aneuploidy correlating to poorer response, enabling personalized immunotherapy and radiotherapy regimens with demonstrated survival improvements in non-small cell lung cancer.
ADVANTAGES
- Enhanced prediction for low TMB tumor patients
- Independent prognostic value beyond traditional biomarkers
- Supports personalized immunotherapy and radiotherapy strategies
- Validated clinical trial and multi-cancer applicability
- Accessible genomic scoring methodology with open-source analysis code
- Facilitates improved survival outcomes through treatment optimization
APPLICATIONS
- Immunotherapy response prediction in non-small cell lung cancer
- Guidance of combined radiotherapy and immune checkpoint blockade regimens
- Stratification tool for diverse solid tumor immunotherapy patient selection